Ropeginterferon for Treatment Free Remission

NCT ID: NCT07105319

Last Updated: 2025-08-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 65 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-11-30
• Study Completion Date: 2025-07-30

Brief Summary

Ropeginterferon is a long-acting next-generation mono-pegylated interferon alfa-2b consisting of one isoform produced by PharmaEssentia Co. and the pegylated (PEG) formulations that require less frequent administration and have improved efficacy and tolerability.

In this study, patients in the investigational arm will receive Ropeginterferon subcutaneously with 250 μg at week 0, 350 μg at week 2, 500 μg at week 4, and thereafter 500 μg bi-weekly until week 24.

Detailed Description

This is a pilot, randomized, two-arm, prospective study with or without Ropeginterferon in CML patients who have sustained MR4.5 for 24 months or more with TKIs.

The patients will be randomized to either

1. Investigational arm with Ropeginterferon (50 patients): Patients will be treated with 250 μg at week 0, 350 μg at week 2, and then 500μg at week 4, and thereafter bi-weekly subcutaneous injection until week 24

2. Comparator arm (50 patients): Patients will be followed with no further CML treatment.

Conditions

CML (Chronic Myelogenous Leukemia)

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

randomized two-arm prospective study with/without Ropeginterferon in CML patients

The patients will be randomized to a ratio of 1:1 for each group

1. Investigational arm with Ropeginterferon (50 patients): Patients will be treated with 250 μg at week 0, 350 μg at week 2, and then 500 μg at week 4, and thereafter bi-weekly subcutaneous injection until week 24

2. Comparator arm (50 patients): Patients will be followed with no further CML treatment

Group Type: EXPERIMENTAL

Ropeginterferon

Intervention Type: DRUG

1. Investigational arm with Ropeginterferon (50 patients): Patients will be treated with 250 μg at week 0, 350 μg at week 2, and then 500 μg at week 4, and thereafter bi-weekly subcutaneous injection until week 24

2. Comparator arm (50 patients): Patients will be followed with no further CML treatment

Interventions

Ropeginterferon

1. Investigational arm with Ropeginterferon (50 patients): Patients will be treated with 250 μg at week 0, 350 μg at week 2, and then 500 μg at week 4, and thereafter bi-weekly subcutaneous injection until week 24

2. Comparator arm (50 patients): Patients will be followed with no further CML treatment

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

A patient must satisfy all the following criteria to be enrolled in the study.

1. New CML-CP at diagnosis

2. Patients aged 19 or more and 75 or less

3. BCR-ABL1 transcripts with e13a2 or e14a2 transcripts

4. Sustained MR4.5 for 24 months or more

5. Signed written informed consent

Exclusion Criteria

• 1) Any contraindication to any of the interferon 2) Documented autoimmune disease at screening or in the medical history 3) Clinically relevant pulmonary infiltrates, pneumonia, and pneumonitis at screening 4) Systemic infections, e.g. hepatitis B, hepatitis C, or HIV at screening 5) Any investigational drug less than 6 weeks before the first dose of study drug or not recovered from effects of prior administration of any investigational agent 6) History or presence of depression requiring treatment with antidepressant 7) Any risk of suicide at screening or previous suicide attempts 8) Any significant morbidity or abnormality which may interfere with the study participation 9) Pregnancy and breast-feeding females of reproductive potential and males not using effective means of contraception 10) History of active substance or alcohol abuse within the last year 11) Evidence of severe retinopathy (e.g. cytomegalovirus retinitis, macular degeneration) or clinically relevant ophthalmological disorder (due to diabetes mellitus or hypertension) 12) Thyroid dysfunction not adequately controlled 13) History of major organ transplantation 14) History of uncontrolled severe seizure disorder 15) Leukocytopenia at the time of screening (count: < 4.0 x 109/L) 16) Thrombocytopenia at the time of screening (count: < 100 x 109/L) 17) History of other malignant diseases except for CML, including solid tumors and hematological malignancies (except basal cell and squamous cell carcinomas of the skin and carcinoma in situ of the cervix that has been completely excised and is considered cured) within the last 3 years

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dong-Wook Kim

OTHER

Sponsor Role: lead

Responsible Party

Dong-Wook Kim

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Eulji University Hospital

Uijeongbu-si, Gyeonggi-do, South Korea

Countries

South Korea

Other Identifiers

UEMC-2021-09-025

Identifier Type: -

Identifier Source: org_study_id